https://www.selleckchem.com/pr....oducts/cct245737.htm
Rheumatoid arthritis (RA) is a systemic autoimmune disease. The combination therapy of methotrexate (MTX) and Janus kinase inhibitor (JAKi) is commonly used. Patients with RA are at increased risk of malignancy, however, it remains unclear whether the combination therapy is associated with a higher risk. To assess the malignancy risk among patients with RA receiving combination therapy of JAKi and MTX compared to MTX alone. PubMed, Cochrane and Embase were thoroughly searched for randomized controlled trials (RCTs) in patients with RA
Like
Comment
Share
